Zynlonta

Monitor for edema or effusions; withhold if Grade ≥2 reaction occurs until resolved. Consider diagnostic imaging if symptoms of pleural or pericardial effusion develop. Risk of severe myelosuppression. Monitor CBCs during therapy. Monitor for infections; withhold if Grade 3 or 4 infection occurs until resolved. Monitor for cutaneous reactions (including photosensitivity); withhold if Grade 3 reaction occurs until resolved. Advise to minimize or avoid exposure to direct natural or artificial sunlight. Avoid extravasation. Mild hepatic impairment: monitor. Moderate/severe hepatic impairment, severe renal impairment, ESRD with or without dialysis: not studied. Embryo-fetal toxicity. Advise to use effective contraception during and for 10 months (females of reproductive potential) or for 7 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 3 months after the last dose).